- Home
- ARMP
as 11-14-2024 4:00pm EST
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 80.0M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 8.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.93 - $4.48 | Next Earning Date: | 11-13-2024 |
| Revenue: | $3,719,000 | Revenue Growth: | -10.71% |
| Revenue Growth (this year): | -32.44% | Revenue Growth (next year): | 83.33% |
Latest Armata Pharmaceuticals Inc. News
ARMP Breaking Stock News: Dive into ARMP Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
PR Newswire
3 days ago
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
PR Newswire
16 days ago
Armata Pharmaceuticals Announces Structural Biology Publication
Zacks
2 months ago
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
PR Newswire
2 months ago
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PR Newswire
3 months ago
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
PR Newswire
3 months ago
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
PR Newswire
3 months ago
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
Compare ARMP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARMP Armata Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.